Polyphor increases IPO size to meet buyer demand
Polyphor, the Swiss pharmaceutical company, is increasing the size of its IPO by Sfr15m due to “strong demand” from institutional investors.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: